Home Cart Sign in  
Chemical Structure| 3060-46-6 Chemical Structure| 3060-46-6

Structure of N-Me-Leu-OH
CAS No.: 3060-46-6

Chemical Structure| 3060-46-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Product Citations

Zhou, Bin ; Shetye, Gauri ; Yu, Yang ; Santarsiero, Bernard D. ; Klein, Larry L. ; Abad-Zapatero, Cele , et al.

Abstract: This study represents a systematic chem. and biol. study of the rufomycin (RUF) class of cyclic heptapeptides, which our anti-TB drug discovery efforts have identified as potentially promising anti-TB agents that newly target the caseinolytic protein C1, ClpC1. Eight new RUF analogs, rufomycins NBZ1-NBZ8, as well as 5 known peptides were isolated and characterized from the Streptomyces atratus strain MJM3502. Advanced Marfey's and X-ray crystallog. anal. led to the assignment of the absolute configuration of the RUFs. Several isolates exhibited potent activity against both pathogens M. tuberculosis H37Rv and M. abscessus, paired with favorable selectivity (selectivity index >60), which collectively underscores the promise of the rufomycins as potential anti-TB drug leads.

Purchased from AmBeed: ; ; ; 621-44-3

Alternative Products

Product Details of [ 3060-46-6 ]

CAS No. :3060-46-6
Formula : C7H15NO2
M.W : 145.20
SMILES Code : CC(C)C[C@H](NC)C(O)=O
MDL No. :MFCD00065919
InChI Key :XJODGRWDFZVTKW-LURJTMIESA-N
Pubchem ID :2777993

Safety of [ 3060-46-6 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Computational Chemistry of [ 3060-46-6 ] Show Less

Physicochemical Properties

Num. heavy atoms 10
Num. arom. heavy atoms 0
Fraction Csp3 0.86
Num. rotatable bonds 4
Num. H-bond acceptors 3.0
Num. H-bond donors 2.0
Molar Refractivity 40.34
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

49.33 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

1.68
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

-1.17
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

0.71
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

-1.47
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

0.32
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

0.01

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

0.26
Solubility 265.0 mg/ml ; 1.82 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Highly soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

0.63
Solubility 615.0 mg/ml ; 4.24 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Highly soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-0.95
Solubility 16.4 mg/ml ; 0.113 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

Yes
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

No
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

No
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

No
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

No
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-8.02 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

1.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.55

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

0.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<1.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

1.52

Application In Synthesis of [ 3060-46-6 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 3060-46-6 ]

[ 3060-46-6 ] Synthesis Path-Downstream   1~54

  • 2
  • [ 3060-46-6 ]
  • [ 70-34-8 ]
  • [ 69935-32-6 ]
  • 3
  • [ 674-82-8 ]
  • [ 3060-46-6 ]
  • [ 35141-03-8 ]
  • 5
  • [ 3060-46-6 ]
  • [ 89941-16-2 ]
  • 6
  • [ 60643-14-3 ]
  • [ 3060-46-6 ]
  • 7
  • Sporidesmolsaeure C; L-α-Hydroxy-isocaproyl-Val-N-methyl-Leu [ No CAS ]
  • [ 3060-46-6 ]
  • 9
  • [ 3060-46-6 ]
  • [ 69146-58-3 ]
  • [ 141849-38-9 ]
  • 12
  • (S)-2-(2-Aza-bicyclo[2.2.1]hept-5-en-2-yl)-4-methyl-pentanoic acid [ No CAS ]
  • [ 3060-46-6 ]
  • [ 542-92-7 ]
  • 13
  • (2S,2'S)-N-<2'-(methylamino)-4'-methylpentanoyl>bornane-10,2-sultam [ No CAS ]
  • [ 3060-46-6 ]
  • 14
  • [ 3060-46-6 ]
  • [ 79-04-9 ]
  • [ 138062-83-6 ]
  • 15
  • Cyclosporin L [ No CAS ]
  • [ 72-18-4 ]
  • [ 2480-23-1 ]
  • [ 3060-46-6 ]
  • (2s)-2-Amino-2-<(2R,3R)-5-ethyl-2,3,4,5-tetrahydro-3-methylfuryl>essigsaeure [ No CAS ]
  • 16
  • Cyclosporin Z [ No CAS ]
  • [ 72-18-4 ]
  • [ 2480-23-1 ]
  • [ 3060-46-6 ]
  • N-Methyl-L-2-aminooctansaeure [ No CAS ]
  • 17
  • [ 3060-46-6 ]
  • [ 407-25-0 ]
  • [ 74530-79-3 ]
  • 18
  • [ 3060-46-6 ]
  • [ 115-11-7 ]
  • [ 42807-86-3 ]
  • 19
  • [ 66866-66-8 ]
  • [ 3060-46-6 ]
YieldReaction ConditionsOperation in experiment
The following can be prepared in a similar way: (S)-Z-N-Methylglycine, (S)-Z-N-methylalanine, (S)-Z-N-methyl-S-benzylcysteine; (S)-Z-N-methylleucine, (S)-Z-N-methylmethionine, (S)-Z-N-methyl-O-benzylthreonine.
0.85 g (46%) methyl-L-leucine (NPC 15273) A suspension of N-[(9H-fluoren-9-ylmethoxy)carbonyl]-L-leucine (1.67 g, 5 mmol) in toluene(100 ml) was charged with paraformaldehyde (1 g, 33.3 mmol) and 4-toluenesulfonic acid (100 mg, catalytic). The mixture was refluxed for 30 minutes in a Dean Stark apparatus for azeotropic distillation. The solution was washed with a saturated solution of sodium bicarbonate (*2), dried over magnesium sulfate and evaporated. The resulting oil in a 1:1 mixture of chloroform:trifluoroacetic acid (50 ml), at room temperature, was charged with triethylsilane (2.38 ml, 15 mmol). Stirring was continued for 22 hr. The solvents were removed in vacuum and the oil was crystallized from a mixture of ether:hexane. Recrystalyzation from EtOAc:hexane afforded 0.85 g (46%) of the product as a colorless solid, mp 101-3 C.
Characterising data Physical and spectral properties of MM 45289 after drying over P2O5: FAB-MS (glycerol/thioglycerol/trifluoroacetic acid) MH+1557+-1 Molecular Weight: 1556 Molecular Formula: C73H89N10O26Cl UV (H2O) lambdamax280 nm (epsilon 6215) [alpha]D20 -118 (c = 0.97% in H2O) IR (kBr) 1660, 1590, 1500, 1070 cmmin1 1H NMR in DMSO d6 at 358K. Tetramethylsilane as internal standard. deltaH 8.45 (1H, broad s), 8.23 (1H, br d, J ca.5Hz), 7.95 (1H, br d, J ca.5Hz), 7.63 (1H, d, J 8.0Hz), 7.52 (1H, d, J 8.3Hz), 7.39 (1H, s), 7.33 (1H, br d), 7.23 (1H, d, J 8.3Hz), 7.12 (1H, s), 7.1 (1H, br d), 6.97 (1H, d, J 8.0Hz), 6.76 (1H, dd, J 8.4 and 2.0Hz), 6.68 (1H, d, J 8.4Hz), 6.45 (1H, d, J 2.0Hz), 6.33 (1H, d, J 2.0Hz), 5.68 (1H, br), 5.63 (1H, s), 5.50 (1H, d, J 7.4Hz), 5.43 (1H, s), 5.27 (2H, overlapping), 5.13 (1H, d, J ca.2Hz), 4.70 (2H, overlapping), 4.50 (1H, d, J 6Hz), 4.47 (1H, d, J 6.1), 4.33 (1H, br), 4.21 (1H, br), 4.13 (1H, dq, J 6.0 and 9.6Hz), 3.75 - 3.30 (7H, overlapping), 3.00 (1H, dd, J 7.8 and 5.8Hz) 2.88 (1H, d, J 9.6Hz), 2.86 (lH, d, J 9.6Hz), 2.58 (lH, dd, J 15.8 and 4.0Hz), 2.32 (3H, s), 2.17 (lH, dd, 15.8 and 6.8Hz), 1.90 (1H, br d, J ca.13Hz), 1.82 (1H, d, J 13.7Hz), 1.77 (1H, m), 1.60 (2H, overlapping, J 13.5 and 4.4Hz), 1.52 (1H, m), 1.42 (1H, m), 1.18 (3H, d, J 5.9Hz), 1.13 (6H, s), 1.09 (3H, d, J 6.0Hz), 0.92 (3H, d, J 6.6Hz), 0.89 (3H, d, J 6.6Hz) ppm. Acid Hydrolysis (6MHCl/110/18hrs/N2/sealed tube) gives aspartic acid and N-methyl leucine. Physical and spectral data on MM 47756: FAB-Ms (thioglycerol/glycerol) MH+ 1523+-1 Molecular Weight: 1522 Molecular Formula: C73H90N10O26 1H NMR in DMSO d6 at 353K, Tetramethylsilane as internal standard. Inter alia 7.61 (2H, d, J ca.8.0Hz), 7.4 - 7.2 (3H, overlapping m), 7.13 (1H, dd, J 8.0 and 2.0Hz), 7.10 (1H, d, J 2.0 Hz), 7.07 (1H, dd, J 8.0 and 2.0Hz), 6.97 (1H, dd, J 8.0 and 2.0Hz), 6.76 (1H, dd, J 8.5 and 2.0Hz), 6.68 (1H, d, J 8.5Hz), 6.40 (1H, d, J 2.2Hz), 6.35 (1H, d, J 2.2Hz) ppm.
The following compounds can be prepared in a similar way: (S)-Z-N-Methylalanine; (R)-Z-N-Methylalanine; (+/-)-Z-N-Methylalanine; (S)-Z-N-Methylleucine; (R)-Z-N-Methylleucine; (+/-)-Z-N-Methylleucine; Z-N-Methylglycine; ...

  • 22
  • [ 74-89-5 ]
  • d-α-bromo-isocaproic acid [ No CAS ]
  • [ 3060-46-6 ]
  • 23
  • N-p-toluenesulfonyl-N-methyl-L-leucine methyl ester [ No CAS ]
  • [ 3060-46-6 ]
  • 24
  • p-toluenesulfonyl-methyl-l-leucine [ No CAS ]
  • [ 3060-46-6 ]
  • 25
  • [ 3060-46-6 ]
  • L-amino acid oxide ase [ No CAS ]
  • [ 816-66-0 ]
  • [ 74-89-5 ]
  • 26
  • [ 7647-01-0 ]
  • [ 64143-96-0 ]
  • [ 3060-46-6 ]
  • [ 104-15-4 ]
  • 27
  • [ 10034-85-2 ]
  • [ 64143-96-0 ]
  • phosphonium iodide [ No CAS ]
  • [ 3060-46-6 ]
  • [ 106-45-6 ]
  • 29
  • [ 278175-37-4 ]
  • [ 3060-46-6 ]
  • 30
  • [ 3060-46-6 ]
  • [ 100-51-6 ]
  • [ 48168-99-6 ]
  • 31
  • 2-(9<i>H</i>-fluoren-9-ylmethoxycarbonylamino)-3-trityloxy-propionic acid pentafluorophenyl ester [ No CAS ]
  • [ 3060-46-6 ]
  • Fmoc-Ser(Trt)-N-MeLeu-OH [ No CAS ]
  • 32
  • [ 3060-46-6 ]
  • [ 219813-88-4 ]
  • 33
  • [ 3060-46-6 ]
  • [ 435342-52-2 ]
  • 34
  • [ 3060-46-6 ]
  • (S)-3-((2S,3R,4R,5S)-5-{(S)-2-[((S)-2-Amino-3-methyl-butyryl)-methyl-amino]-4-methyl-pentanoylamino}-2,3,4,6-tetrahydroxy-hexanoylamino)-3-phenyl-propionic acid [ No CAS ]
  • 35
  • [ 3060-46-6 ]
  • N-[(2S,3R,4R,5S)-5-[N-methyl-N-(N-tert-butoxycarbonyl-L-valyl)-L-leucyl]amino-2,3,4,6-tetrahydroxyhexanoyl]-β-D-phenylalanine [ No CAS ]
  • 36
  • [ 212896-16-7 ]
  • [ 3060-46-6 ]
  • 37
  • [ 2018-66-8 ]
  • [ 3060-46-6 ]
  • 39
  • (2S,2'S)-N-<2'-<(hydroxy)(methyl)amino>-4'-methylpentanoyl>bornane-10,2-sultam [ No CAS ]
  • [ 3060-46-6 ]
  • 40
  • [ 3060-46-6 ]
  • (S)-2-[(2,3-Bis-benzyloxy-benzoyl)-methyl-amino]-4-methyl-pentanoic acid 2,5-dioxo-pyrrolidin-1-yl ester [ No CAS ]
  • 42
  • [ 3060-46-6 ]
  • [ 3200-76-8 ]
  • 43
  • [ 3060-46-6 ]
  • [ 84569-89-1 ]
  • 44
  • [ 3060-46-6 ]
  • [ 82414-76-4 ]
  • 45
  • [ 3060-46-6 ]
  • [ 84569-87-9 ]
  • 46
  • [ 3060-46-6 ]
  • [ 84569-85-7 ]
  • 47
  • [ 3060-46-6 ]
  • [ 84569-83-5 ]
  • 48
  • [ 3060-46-6 ]
  • [ 82414-81-1 ]
  • 49
  • [ 3060-46-6 ]
  • [ 82414-78-6 ]
  • 50
  • [ 61-90-5 ]
  • [ 3060-46-6 ]
  • 51
  • [ 2743-42-2 ]
  • [ 3060-46-6 ]
  • 52
  • [ 123-91-1 ]
  • [ 3060-46-6 ]
  • [ 35026-08-5 ]
YieldReaction ConditionsOperation in experiment
100% In hydrogenchloride; methanol; a) <strong>[3060-46-6]N-methyl-L-leucine</strong> methyl ester <strong>[3060-46-6]N-methyl-L-leucine</strong> (1.3 g, 8.95 mmol) was dissolved in 4M HCl, 1,4-dioxane (10 mL) and methanol (10 mL). The solution was stirred overnight at room temperature, then concentrated to afford the title compound as a white solid (100%). MS (ESI): 160.0 (M+H)+.
  • 53
  • [ 3060-46-6 ]
  • [ 7664-93-9 ]
  • [ 115-11-7 ]
  • [ 42807-86-3 ]
YieldReaction ConditionsOperation in experiment
19.41 g (94%) With potassium hydroxide; In 1,4-dioxane; water; Step 1: The preparation of (S)-2-(4-tert-butylbenzyl-methyl-amino)-4-methyl-pentanoic acid (IIc) STR30 Step i: (S)-4-Methyl-2-methylamino-pentanoic acid (15 g, 103 mmol) was dissolved in dioxane (100 mL), cooled to 0 C., then treated with H2 SO4 (10 mL) and isobutylene (100 mL). The mixture was stirred and allowed to come to room temperature over 1 hour. The reaction was vented and poured into a rapidly stirred mixture of KOH (20.7 g) in water, ice, and ether. The solution was filtered, and more ether was added. The organic layer was dried over Na2 SO4 and concentrated to give 19.41 g (94%) of (S)4-methyl-2-methylamino-pentanoic acid tert-butyl ester. MS: 202 (M+1 for C11 H23 N1 O2); TLC SiO2, Rf 0.52 (10% MeOH/CH2 Cl2).
  • 54
  • [ 3060-46-6 ]
  • [ 210529-62-7 ]
  • D-FDVA-L-NMe-Leu [ No CAS ]
 

Historical Records

Technical Information

Categories